REMVULIMORGENE AUTOLEUCEL
UNII NKC6YR89C7

Substance Identification & Data

This profile provides standardized clinical and technical data for Remvulimorgene Autoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) NKC6YR89C7.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

NKC6YR89C7

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

REMVULIMORGENE AUTOLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C206977

National Cancer Institute reference terminology for clinical and research data.

INN ID

12777

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Remvulimorgene Autoleucel

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Remvulimorgene Autoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Remvulimorgene Autoleucel

Common Names & Synonyms

autologous peripheral blood mononuclear cells (PBMCs) obtained by apheresis and engineered into enhanced antigen presenting cells (eAPCs) by loading with five messenger RNAs (mRNAs) individually encoding human papillomavirus type 16 (HPV16) E6 protein, HPV16 E7 protein, human CD86, membrane-bound interleukin 2 (mbIL-2) and membrane-bound interleukin 12 (mbIL-12). Interleukin 2 (IL-2) and interleukin 12 (IL-12) are rendered membrane-bound (mb) by fusion to the transmembrane domain of the transferrin receptor with an interceding (G4S)3 linker. The mRNAs are delivered using a microfluidic membrane deformation technique that temporarily disrupts the cell membrane. Each mRNA comprises a 5'-cap, a synthetic 5' untranslated region containing a Kozak sequence, a coding region and a 3' untranslated region (UTR) derived from the murine alpha globin UTR. The cell population phenotype is CD45+, comprising primarily T lymphocytes (CD3+), monocytes (CD14+), natural killer (NK) cells (CD56+), and B lymphocytes (CD19+)

remvulimorgene autoleucel [INN]

External Clinical & Regulatory Resources

Previous UNIINKB67Q143T

Next UNIINKD0AX51DA